QUOTE AND NEWS
TheStreet.com  Sep 17  Comment 
NEW YORK (TheStreet) -- Shares of Salix Pharmaceuticals Ltd. are up 1.37% to $158 in pre-market trade as some of the top 20 investors are threatening to vote down a proposed deal to buy a unit of Cosmo Pharmaceuticals, and are pressing Salix to...
Reuters  Sep 16  Comment 
Some of the top 20 investors at Salix Pharmaceuticals Ltd are threatening to vote down a proposed deal to buy a unit of Cosmo Pharmaceuticals SpA , and are pressing Salix to...
StreetInsider.com  Sep 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Salix+Pharma+%28SLXP%29+UCERIS+Rectal+Foam+Granted+FDA+Approval/9833707.html for the full story.
FiercePharma  Sep 15  Comment 
Salix Pharmaceuticals, which has its hands full with a tax inversion merger and the integration of Santarus, will hand off Canadian sales of some of its drugs to India's Lupin. The package includes Salix's opioid constipation drug Relistor, a drug...
The Hindu Business Line  Sep 14  Comment 
Ties up with US-based Salix to sell two remedies
The Times of India  Sep 13  Comment 
Lupin Ltd, India's fourth-largest drugmaker by sales, said it entered into an exclusive deal to market some of US firm Salix Pharmaceuticals Inc's products in Canada to expand its footprint in that region.
StreetInsider.com  Sep 12  Comment 
The following is a list of notable articles to help get you through the lunch hour: S&P Upgrades Greece from 'B-' to 'B'; Risks to Fiscal Consolidation Have Faded -> Read this! Credit Suisse Starts Salix Pharmaceuticals (SLXP) at Underperform;...
Benzinga  Sep 12  Comment 
Analysts at Credit Suisse initiated coverage on Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) with an Underperform rating and $139 price target Friday. Ronak H. Shah outlined the causes for the upgrade: An acquisition by AGN is unlikely....
Reuters  Sep 12  Comment 
(Corrects to say Salix will get upfront payment from Lupin in second paragraph)
The Hindu Business Line  Sep 12  Comment 
SeekingAlpha  Sep 8  Comment 
By Stephen Simpson, CFA: For a biotech that has reported encouraging clinical results and seeks to address a significant market, Synergy Pharmaceuticals (NASDAQ:SGYP) can't get much love. I can appreciate that there's a funding overhang here and...




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing, and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases. The company has a number of products currently approved for sales. These include Colazal (balsalazide disodium) for the treatment of mild to moderate active ulcerative colitis, Azasan (azathioprine) immuno-suppressive therapy for renal homo-transplant rejection and rheumatoid arthritis, and Anusol/Proctocort (hydrocortisone) for the relief of inflammatory dermatoses and hemorrhoids. In May 2004, the company received final Food and Drug Administration (FDA) approval for Xifaxan (rifaximin), an oral antibiotic for the treatment of traveler's diarrhea. Salix Pharmaceuticals is working on additional indications for Xifaxan, as well as a granulated formulation of mesalamine a common treatment option for ulcerative colitis.

Salix subsequently added new products to its portfolio including Visicol, indicated for colon cleansing prior to colonoscopy OsmoPrep, a next-generation Visicol which was launched in June 2006 and MoviPrep, a liquid bowel cleansing agent which was launched in October 2006. While Visicol and OsmoPrep were acquired by the company through its merger with InKine Pharmaceutical, exclusive U.S. in-licensing rights for MoviPrep were acquired from Norgine B.V. Recent additions to the product portfolio include Sanvar IR, indicated for the treatment of acute esophageal variceal bleeding (EVB) two hospital-based products, Pepcid Oral Suspension (indicated for several gastrointestinal indications including the treatment of duodenal ulcer, benign gastric ulcer and gastroesophageal reflux disease) and Diuril Oral Suspension (an adjunctive therapy in edema associated with several conditions including hepatic cirrhosis), from Merck and metoclopramide Zydis, indicated for short term (4 12 weeks) therapy for adults with symptomatic documented gastroesophageal reflux who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastric stasis.

Salix focuses primarily on the U.S. pharmaceutical market, promoting its drugs through its specialized sales force. Management also seeks to form strategic alliances to market its products outside the U.S. in order to avoid the significant costs, risks, and infrastructure inherent in assembling an international sales force. Salix is located in Morrisville, NC and employs roughly 240 professionals.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki